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Summary
The intracellular signaling events causing tumor cells to become metastatic are not well understood. N-cadherin and FGF-2
synergistically increase migration, invasion, and secretion of extracellular proteases in breast tumor cells. Here, we define
a metastatic signaling cascade activated by N-cadherin and FGF-2. In the presence of N-cadherin, FGF-2 caused sustained
activation of the MAPK-ERK pathway, leading to MMP-9 gene transcription and cellular invasion. N-cadherin prevented
the FGF receptor (FGFR) from undergoing ligand-induced internalization, resulting in increased FGFR-1 stability. Association
of FGFR-1 with N-cadherin was mediated by the first two Ig-like domains of FGFR-1. These results suggest that protection
of the FGFR-1 from ligand-induced downregulation by N-cadherin enhances receptor signaling and provides a mechanism
by which tumor cells can acquire metastatic properties.
Introduction possibility was strengthened by the demonstration that secre-
tion of the matrix metalloprotease, MMP-9, was elevated upon
FGF-2 treatment of N-cadherin-expressing tumor cells (HazanAberrant cellular growth is a primary cause in the development
of malignant tumors, but additional events take place which et al., 2000).
Similarities between tumor invasion and physiologic re-enable tumor cells to invade tissue barriers and metastasize to
distant sites. These events include detachment of cells from sponses, such as neurite outgrowth, have been noted (Taguchi
et al., 2000). The synergistic activity of FGFR and N-cadherinthe primary tumor, the crossing of tissue boundaries, entrance
and exit from the circulatory system, the infiltration of distant was shown to generate intracellular signals that promote neu-
ronal growth (Williams et al., 1994; Doherty et al., 2000). Theorgans, and the formation of metastatic implants (Liotta et al.,
1991). functional cooperativity between the FGFR with N-cadherin in
neurite outgrowth was postulated to involve the HAV motif onIt has been hypothesized that one of the factors contributing
to the escape of nascently metastasizing tumor cells from the FGFR and the fourth extracellular domain (EC4) on N-cadherin,
based on the inhibitory effect of peptides derived from the HAVprimary tumor mass is reduced tumor cell adhesion caused by
the loss of the cell adhesion molecule, E-cadherin (for review, domain as well as function-blocking anti-EC4 antibodies on
neuronal growth (Williams et al., 2001). The findings from thesesee Takeichi, 1993). However, a related adhesion molecule,
N-cadherin, is upregulated in invasive cancer cell lines (Hazan neurite outgrowth studies were consistent with those of tumor
invasion, which showed that the N-cadherin EC4 domain waset al., 1997; Tran et al., 1999) and tumors (Li et al., 2001; Tomita
et al., 2000), and has effects on cellular behavior that are beyond required for the migration of cells stimulated by N-cadherin (Kim
et al., 2000).a simple change in adhesive specificity. N-cadherin induced an
invasive morphology in squamous tumor cells (Islam et al., 1996) Studies have linked the activation of the MAPK-ERK path-
way to the transcription of matrix metalloproteases (Wes-and stimulated migration, invasion (Hazan et al., 2000; Nieman
et al., 1999), and metastasis of breast cancer cells (Hazan et al., termarck and Kahari, 1999), which are critical mediators of inva-
sive growth (Chang and Werb, 2001; Stetler-Stevenson et al.,2000). The effects of N-cadherin were exacerbated by FGF-2,
suggesting that N-cadherin and FGFR-1 synergize to generate 1993). MAP kinases are known to play a pivotal role in a diversity
of cellular responses, including cell proliferation, differentiation,signals which alter invasive behavior (Hazan et al., 2000). This
S I G N I F I C A N C E
For tumor cells to metastasize to distant sites, they must detach from the primary tumor. It is thought that reduced cell adhesion,
caused by the loss of E-cadherin, initiates tumor invasiveness. However, a related adhesion molecule, N-cadherin, is upregulated
in invasive tumors and has consequences on cellular behavior other than a simple change in cellular adhesive specificity. N-cadherin
interacts with the FGFR-1 and attenuates its ligand-induced downregulation, resulting in sustained MAPK-ERK activation, MMP-9 gene
transcription, and cellular invasiveness. Solving the molecular details of the N-cadherin-FGFR interaction may provide valuable
approaches for controlling tumor metastasis.
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Figure 1. FGF-2-mediated expression of MMP-9 and sustained ERK phosphorylation is dependent on N-cadherin
A: MCF-7-N-cad cells (top) or MCF-7-neo cells (bottom) were treated with the indicated growth factors at 50 ng/ml, and MMP-9 secretion was assessed
by zymmography.
B: MCF-7-N-cad (a and c) or MCF-7-neo (b and d) were treated with the indicated concentrations of FGF-2, including 5 g/ml heparin, for 10 min (a and
b) or 18 hr (c and d). Lysates were electrophoresed and probed with antibodies to phospho-ERK1/2 (P-MAPK, left) or total MAPK (T-MAPK, right).
C: Clonal MCF-7-N-cad cells (top), an aclonal population of stable N-cadherin transfectants (N-cad-mass, middle), or an aclonal population of stable
vector transfectants (Neo-mass, bottom) were treated for 10 min with the indicated concentrations of FGF-2 and processed as above.
D: MCF-7-N-cad cells were treated with the indicated concentrations of FGF-2 for 18 hr and MMP-9 production was assessed by zymmography.
senescence, migration, and invasion (Chang and Karin, 2001). other growth factors, such as insulin, EGF, HGF, and PDGF
(Figure 1A, top panel, lanes 3–6, respectively), did not stimulateOne current belief is that differences in the magnitude and/or
duration of MAPK-ERK signaling determine signal specificity, MMP expression, despite the ability of each of these growth
factors to elicit signaling in these cells (see Figure 2A). Controlthus creating a repertoire of responses (Schaeffer and Weber,
1999). We postulated that the synergy between N-cadherin and MCF-7 cells (MCF-7-neo) exhibited only low MMP levels in
response to any of the growth factors tested (Figure 1A, bottomFGFR-1 might alter the duration of the MAPK-ERK signal, thus
leading to metastasis. panel, lanes 1–6).
We show that N-cadherin and FGFR-1 cooperate to activate
a signaling cascade that results in tumor invasion. N-cadherin Sustained MAPK activation leads to MMP-9 gene
associates with the FGFR-1 via the extracellular first two Ig-like expression and invasiveness
domains on the FGFR-1. As a consequence of this interaction, The transcription of MMP genes depends on MAPK-ERK activity
FGFR-1 is not efficiently internalized by FGF-2, causing sustained (Westermarck and Kahari, 1999). We examined whether FGF-2
cell surface expression of FGFR-1, leading to persistent MAPK- induction of MMP-9 expression in N-cadherin-expressing cells
ERK activation, MMP-9 expression, and tumor cell invasion. was accompanied by changes in MAPK-ERK activity. The levels
of phosphorylated ERK (P-MAPK) in N-cadherin-expressing
MCF-7 cells (MCF-7-N-cad; Figures 1Ba and 1Bc) were com-Results
pared to those in control MCF-7 cells (MCF-7-neo; Figures 1Bb
and 1Bd) in response to increasing concentrations of FGF-2 atN-cadherin and FGFR-1 initiate metastatic signals
FGF-2 stimulated the expression of MMP-9 in MCF-7 breast two time points, 10 min (Figures 1Ba and 1Bb) and 18 hr (Figures
1Bc and 1Bd). As a control, the total levels of ERK (T-MAPK)cancer cells when the cells were transfected with N-cadherin
(Hazan et al., 2000). We determined whether other growth fac- were determined (Figure 1B, right panels). As little as 10 ng/ml
FGF-2 stimulated an increase in P-ERK in MCF-7-N-cad cellstors could stimulate MMP-9 secretion in N-cadherin transfected
MCF-7 (MCF-7-N-cad) cells. While FGF-2 elicited an MMP-9 after 10 min of treatment (Figure 1Ba, lane 3). Control cells
required a higher concentration of FGF-2 (50 ng/ml) and stillresponse in MCF-7-N-cad cells (Figure 1A, top panel, lane 2),
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Figure 2. FGF-2, but not other growth factors, syn-
ergizes with N-cadherin to promote sustained
MAPK-ERK phosphorylation which leads to
MMP-9 gene transcription
A: MCF-7-N-cad cells (left) or MCF-7-neo cells
(right) were left untreated (lanes 1 and 5) or
treated with the indicated growth factors at 50
ng/ml and were lysed at 10 min (lanes 2 and 6),
2 hr (lanes 3 and 7), or 24 hr (lanes 4, and 8). ERK
phosphorylation was assayed by immunoblot-
ting.
B: MCF-7-N-cad cells were treated for 18 hr with
(lane 3) or without 40 M PD98059 (lanes 1–2) in
the absence (lane 1) or presence (lanes 2–3) of
50 ng/ml FGF-2. MMP-9 activity was assessed by
zymmography (top), and ERK phosphorylation
was determined (bottom).
C: MCF-7-N-cad or MCF-7-neo cells were treated
for 18 hr with or without FGF-2, and the MMP-9
promoter activity was determined using a lucifer-
ase reporter construct.
D: MCF-7-N-cad cells were treated with the indi-
cated agents and MMP-9 promoter activity was
determined by luciferase assay.
elicited a weaker P-ERK signal (Figure 1Bb, lane 4). MAPK in inducing MMP-9 expression in N-cadherin-expressing MCF-7
cells was due to differences in the duration of MAPK-ERK activa-phosphorylation declined after 18 hr to background levels in
control MCF-7-neo cells (Figure 1Bd, lane 4), but it persisted tion. FGF-2 caused a persistent phosphorylation of MAPK in
MCF-7-N-cad cells starting at 10 min and lasting over 24 hrin MCF-7-N-cad cells (Figure 1Bc, lanes 3–4). Changes in MAPK
activation in response to FGF-2 were not due to alterations in (Figure 2A, lanes 2–4), while in control cells, FGF-2-induced
ERK phosphorylation was lost after only 2 hr treatment withthe total pool of MAPK (T-MAPK) in both cell lines (Figures
1Ba–1Bd, lanes 5–8). growth factor (Figure 2A, lanes 6–8). In contrast, EGF, Insulin,
PDGF, and VEGF stimulated short-term ERK phosphorylationN-cadherin sensitized cells to low levels of FGF-2 (1 ng/
ml) (Figure 1C, top panel, lane 2). An aclonal population of that was of similar duration in both MCF-7-N-cad (Figure 2A,
lanes 2–4) and control cells (Figure 2A, lanes 6–8).N-cadherin-transfected MCF-7 cells (N-cad-mass), expressing
10-fold less N-cadherin than MCF-7-N-cad clonal cells (Hazan We confirmed the involvement of the MAPK-ERK pathway
in the regulation of MMP-9 expression using the MEK1 inhibitor,et al., 2000), was also sensitized to FGF-2 (3–10 ng/ml; Figure
1C, middle panel, lanes 3–4). Control aclonal cultures (Neo- PD98059. MCF-7-N-cad cells were treated with FGF-2 for 18
hr in the presence or absence of 40 M PD98059. Treatmentmass) required a higher concentration of FGF-2 (30 ng/ml) to
elicit detectable ERK phosphorylation after 10 min of treatment of MCF-7-N-cad cells with PD98059 blocked the phosphoryla-
tion of MAPK-ERK (Figure 2B, lower panel, lane 3), and inhibitedwith FGF-2 (Figure 1C, lower panel, lane 5). Total pools of MAPK
were not affected by FGF-2 treatment (Figure 1C, lanes 6–10). MMP-9 production in response to FGF-2 (Figure 2B, top panel,
lane 3). Inhibition of another FGF-2-responsive pathway, PLC,The rise in MAPK phosphorylation in MCF-7-N-cad cells was
accompanied by an increase in MMP-9 secretion in MCF-7- by U73122 (Wu et al., 2000) did not reduce ERK phosphorylation
or MMP-9 expression induced by FGF-2 (not shown).N-cad cells in response to FGF-2 (Figure 1D; compare to Figure
1C, top left panel). Increases in MMP-9 levels stimulated by FGF-2 in
N-cadherin-expressing MCF-7 cells were due to MMP-9 geneThe discrepancy between FGF-2 and other growth factors
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transcription. We found a 4-fold increase in MMP-9 promoter N-cadherin protects the FGF receptor from ligand-
induced downregulationactivity in FGF-2-treated MCF-7-N-cad cells, but not in FGF-2-
We determined whether N-cadherin affects the steady statetreated control cells (Figure 2C). Inhibition of ERK by a dominant
levels of FGFR-1 after FGF-2 treatment. A Flag-tagged FGFR-1negative MEK (DN-MEK) or PD 98059 reversed the increase in
construct was transiently expressed in L cells (L), which expressMMP-9 promoter activation by FGF-2 (Figure 2D). Other growth
no known cadherins, N-cadherin (LN), or a nonadhesivefactors such as EGF, PDGF, or VEGF did not activate the MMP-9
N-cadherin mutant (L-NW2A) (Tamura et al., 1998). Cells werepromoter (Figure 2D).
stimulated for 18 hr with FGF-2 and the levels of tagged FGFR-1We would expect that activation of the MAPK-ERK pathway
were assessed by immunoblotting (Figure 4C). MCF-7 cells ex-by an activated form of MEK1 in control MCF-7 cells would
pressing either vector (MCF-7-neo) or N-cadherin (MCF-7-bypass the requirement for N-cadherin and FGFR-1 to stimulate
N-cad), as well as HEK 293T cells, which express endogenousinvasion. Retroviral infection of a constitutively active MEK1
N-cadherin, were also transfected with tagged FGFR-1 and(MEKEL) (Habelhah et al., 2001) in MCF-7 cells increased MEK1
subjected to the same analysis (Figure 4C).levels (Figure 3A, lane 2) and increased MAPK-ERK phosphory-
Incubation of L cells with FGF-2 resulted in downregulationlation (Figure 3A, lane 4) as compared to noninfected MCF-7
of FGFR-1 (Figure 4C, lanes 1–2), consistent with ligand-cells (Figure 3A, lanes 1 and 3). This also led to increased MMP-9
induced receptor degradation (Sorokin et al., 1994). In contrast,production (Figure 3A, lanes 5–6) as well as enhanced invasion
FGF-2 did not downregulate FGFR-1 in LN cells, resulting in
of MCF-7 cells through Matrigel (Figure 3B, right panel), relative
higher levels of FGFR-1 (Figure 4C, lanes 3–4). The mutant
to controls (Figure 3B, left panel). N-cadherin NW2A also supported FGFR-1 stability as much as
We tested whether blockade of MAPK-ERK or MMP-9 would the wild-type N-cadherin (Figure 4C, lanes 5–6), suggesting that
suppress the invasion of MCF-7-N-cad cells in response to the adhesive activity of N-cadherin does not contribute to this
FGF-2 (Figures 3C–3E). FGF-2 stimulated the invasion of MCF- effect. Increases in FGFR-1-Flag expression were also observed
7-N-cad cells through Matrigel-coated (Figure 3Cb) and un- in MCF-7-N-cad cells (Figure 4C, lanes 7–8), but not in MCF-
coated filters (Figure 3Cf) relative to untreated cells (Figures 7-neo cells, following FGF-2 treatment (Figure 4C, lanes 9–10).
3Ca and 3Ce). Inhibitors of MEK1 (40 M PD98059; Figure 3Cc) Finally, FGF-2 treatment of HEK 293T cells also led to increases
or MMP-9 (2 M GM6001; Figure 3Cd) caused fewer cells to in FGFR-1-Flag (Figure 4C, lanes 11–12). The endogenous levels
cross the Matrigel barrier in response to FGF-2. An inactive of -tubulin were found to be unchanged by FGF-2 treatment
GM6001 analog did not block the invasion or migration of FGF-2 of all the cell lines tested (not shown).
treated-MCF-7-N-cad cells (Figures 3D and 3E). Interestingly, N-cadherin did not prevent ligand-induced downregulation
the inhibition of MEK1 (Figure 3Cg) or MMP-9 (Figure 3Ch) had of other growth factor receptors such as EGFR, PDGFR, or
no effect on the FGF-2-stimulated migration of MCF-7-N-cad VEGFR. LN cells were transiently transfected with expression
vectors for these receptors (Figure 4D, lanes 1, 3, and 5, respec-cells through uncoated filters.
tively). Treatment of cells with cognate growth factors at 50 ng/
ml for 18 hr resulted in complete downregulation of each recep-Endogenous N-cadherin and FGFR-1 expression is
tor (Figure 4D, lanes 2, 4, and 6). Thus, N-cadherin interferesassociated with sustained MAPK-ERK activation
only with the ligand-induced downregulation of FGFR-1.by FGF-2
We examined the effect of N-cadherin on ligand-inducedWe compared the kinetics of MAPK-ERK phosphorylation in
internalization of FGFR-1. L or LN cells, transfected withseveral tumor cell lines as a function of N-cadherin expression
FGFR-1, were incubated with saturating amounts of FGF-2 onand FGF-2 stimulation. The T47D and ZR-75-1 breast cancer
ice to allow ligand binding in the absence of internalization.cell lines, the prostate DU145 and LNCap cell lines, and the
Cells were washed of excess FGF-2 and internalization wasmelanoma cell line 888, which express E-cadherin (Figure 4A,
initiated by incubation at 37C for various time points. At eachtop panel, lanes 1–5) but not N-cadherin (Figure 4A, middle
time point, remaining surface-bound FGF-2 was stripped frompanel, lanes 1–5), were compared to the breast MDA-MB-134,
the cell surface, TCA-precipitated, electrophoresed, and immu-
bladder Tsu.Pr-1, and melanoma MeWo tumor cell lines, which
noblotted with an antibody to FGF-2 (Figure 5A). As shown by
express N-cadherin (Figure 4A, middle panel, lanes 6–8) but not densitometric analysis of the immunoblots in Figure 5A, the
E-cadherin (Figure 4A, top panel, lanes 6–8). Most of these kinetics of FGF-2 internalization were much more rapid in L cells
cell lines, except for LNCap, contained the FGFR-1 (Figure 4A, than in LN cells. While 50% of FGF-2 was internalized by 7 min
bottom panel, lanes 2–8) or FGFR-2 (Figure 4A, bottom panel, in L cells, it required a much longer period (30–40 min) for LN
lane 1), which was expressed either as one or three protein cells to internalize FGF-2 to the same extent. Moreover, while
bands. This could be due to alternative splicing of FGFR-1, L cells cleared almost all of the FGF-2 (90%) from the cell surface
often found in tumors (Luqmani et al., 1995), or possibly to by 20–30 min, LN cells still kept 50% of their FGF-2 on
degradation. FGF-2 stimulation of E-cadherin-expressing tumor the cell surface by 30–40 min after the start of internalization
cell lines T47D, ZR-75-1, DU145, LNCap, and 888 resulted in (Figure 5A).
transient phosphorylation of MAPK-ERK after 10 min (Figure To determine whether the reduced internalization of FGFR-1
4B, lanes 1–2), which declined after 18 hr (Figure 4B, lane 3). resulted in increased receptor stability, the half-life of FGFR-1 was
N-cadherin-expressing cell lines, MDA-MB-134, TSU.Pr-1, and measured in L and LN cells transiently expressing FGFR-1 after
MeWo exhibited ERK phosphorylation (Figure 4B, lane 2) that FGF-2 stimulation. Serum-starved cells were treated with 20
was sustained over 18 hr stimulation with FGF-2 (Figure 4B, g/ml cycloheximide together with FGF-2 over a 9 hr period,
lane 3). The total levels of ERK were unaltered by FGF-2 treat- and the levels of FGFR-1 were determined by immunoblotting
at each indicated time point. As shown in Figure 5B, the half-ment (not shown).
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Figure 3. FGF-2 cooperates with N-cadherin in a MAPK-ERK and MMP-9 dependent fashion to promote invasion but not migration
A: In the absence of FGF-2 or N-cadherin (control MCF-7 cells), retroviral infection of a constitutively active MEK1 (MEKEL) caused increased levels of MEK1
(lane 2) and P-ERK (lane 4) relative to uninfected cells (lanes 1 and 3). MEKEL also caused an increase in MMP-9 expression (lane 6) as shown by zymmography
relative to controls (lane 5).
B: Increased invasion as a result of MEKEL (right panel) relative to control invasion (left panel).
C: MCF-7-N-cad cells were untreated (a and e) or treated for 18 hr with 50 ng/ml FGF-2 and 5 g/ml heparin (b and f) in the presence of either 40 M of
PD98059 (c and g), 2 M GM6001 (d and h), or 2 M of an inactive GM6001 analog (D and E). Cells were assayed for their ability to migrate through 8
m porous filters, coated with Matrigel (invasion; a–d) or left uncoated (migration; e–h), toward a chemottractant for a 8 hr period.
(D and E) Quantification of invasion and migration assay. Cells were counted in triplicate wells and in five identical experiments. The bars in D and E
represent mean  SD.
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Figure 4. Sustained ERK activation and FGFR-1
stabilization by FGF-2 correlates with N-cadherin
expression
A: The breast T47D, ZR-75-1, MDA-MB-134, the
prostate DU145, LNCap, the bladder TSU.Pr-1,
and melanoma 888 and MeWo tumor cell lines
were evaluated by immunoblot for the expres-
sion of E-cadherin (top panel), N-cadherin (mid-
dle panel), and FGFR-1 or 2 (bottom panel).
FGFR-1 was present in most cell lines as either
one or three protein bands.
B: ERK phosphorylation was sustained only in the
N-cadherin-positive MDA-MB-134, TSU.Pr-1, and
MeWo cell lines over 18 hr stimulation with FGF-2
(lane 3). The E-cadherin-expressing cell lines
(T47D, ZR-75-1, DU145, LNCap, and 888) exhibited
only a transient ERK activation after FGF-2 treat-
ment. In these cells, ERK phosphorylation was re-
duced after 18 hr (lane 3) relative to 10 min (lane
2) of treatment with FGF-2. Total MAPK levels
were determined in each condition and found
unchanged by FGF-2 treatment (not shown).
C: Mouse L cell fibroblasts (L, lanes 1–2) or L cells
stably transfected with N-cadherin (LN, lanes
3–4) or a nonadhesive N-cadherin mutant
(LNW2A, lanes 5–6) were transiently transfected
with FGFR-1-Flag and then treated for 18 hr with
or without 100 ng/ml FGF-2. MCF-7-N-cad cells
(lanes 7–8), MCF-7-neo cells (lanes 9–10), or 293T
cells (lanes 11–12) were treated similarly. Cells
were harvested and FGFR-1 levels were deter-
mined by immunoblotting of cell extracts using
anti-Flag antibodies.
D: EGFR, PDGFR, or VEGFR expression constructs
were transiently expressed in LN cells and treated
(lanes 2, 4, and 6) with cognate growth factors
or left untreated (lanes 1, 3, and 5). Levels of
receptors before and after treatment with ligand
were evaluated by immunoblotting with specific
antibodies. As loading controls, -tubulin levels
were assessed in each sample from C and D and
found to be unaltered by ligand treatment (not
shown). Molecular weigths (kDa) are indicated.
life of FGFR-1 in L cells is 2 hr after FGF-2 treatment, while We examined the association of endogenous N-cadherin with
FGFR-1 in 293T cells that transiently expressed Flag-taggedin LN cells, the half-life of FGFR-1 is extended to 6 hr after
FGF-2 stimulation. FGFR-1. FGFR-1-Flag immunoreactivity was observed in immu-
noprecipitates with N-cadherin antisera (Figure 6A, lane 3), butWe performed FACS analysis of endogenous FGFR-1 in L
cells, LN cells, and MCF-7 cells with or without N-cadherin, not in those with preimmune sera (Figure 6A, lane1). N-cadherin
using an antibody to the extracellular domain of the FGFR-1 immunoprecipitates from vector-transfected 293T cells did not
(Figure 5C). FGF-2 caused reduction in cell surface expression show any FGFR-1-Flag immunoreactivity (Figure 6A, lane 2).
of FGFR-1 in L cells and MCF-7-neo cells by a mean value of We also examined the interaction of N-cadherin with FGFR-2
30% 8 and 23% 9, respectively (Figure 5C, top left and in HEK 293T and found similar coprecipitation of N-cadherin
right panels, respectively). In contrast, the levels of FGFR-1 in with FGFR-2 as with FGFR-1 (not shown).
N-cadherin-expressing cells and LN and MCF-7-N-cad cells The association of N-cadherin with FGFR-1 was similarly
(Figure 5C, bottom left and right panels) were increased by a tested in N-cadherin-expressing L cells and found to be greater
mean of 50% 10 and 32% 10 respectively. We therefore in FGF-2-treated than untreated cells (Figure 6B, lanes 1–2).
conclude that N-cadherin prevents the FGFR-1 from undergoing FGF-2 remained bound to the N-cadherin-associated FGFR-1
internalization, thus resulting in increased receptor expression as indicated by the reactivity of an anti-FGF-2 antibody with
at the cell surface and enhanced downstream signaling. N-cadherin immunoprecipitates (Figure 6C, lanes 1–2). The in-
crease in FGFR-1 expression in FGF-2-treated LN cells is asso-
ciated with higher levels of phosphorylated FGFR-1 (Figure 6D,N-cadherin and the FGF receptor form a complex
To examine how N-cadherin promotes FGFR-1 stability, we lanes 1–2), suggesting that N-cadherin stabilizes both FGFR-1
expression and function.determined whether the two proteins form a physical complex.
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Figure 5. N-cadherin attenuates FGF-2-induced FGFR-1 internalization and degradation and results in chronic FGFR-1 expression at the cell surface
A: Rate of internalization of FGF-2 in L cells (squares) versus LN cells (diamonds) as determined by cell surface stripping of bound FGF-2 at various time
points after treatment (see Experimental Procedures). (Inset) Immunoblots of cell surface stripped FGF-2 at each time point. Blots were scanned and FGF-2
levels were quantified by densitometry and values expressed as the percent of FGF-2 before transfer of cells to 37C.
B: The effect of N-cadherin on FGF-2-induced degradation of FGFR-1 was measured by treatment of L and LN cells transfected with FGFR-1 with 20 g/
ml cycloheximide and 100 n/ml FGF-2 including 5g/ml heparin for 1 to 9 hr. Cell lysates were harvested and analyzed for FGFR-1 contents by immunoblotting.
Data were normalized to the values of endogenous -tubulin and expressed as the percent of the levels of FGFR-1 before addition of FGF-2 (time 0).
C: Endogenous expression of cell surface-associated FGFR-1 was analyzed by flow cytometry for the binding of an anti-FGFR-1 antibody recognizing the
extracellular domain of FGFR-1. As a negative control, same cells were similarly analyzed for reactivity with preimmune antibody. The histogram plots were
gated on the window shown on the scatter plot at the bottom of the figure.
N-cadherin did not interact with other receptor tyrosine ki- 4 and 6; respectively), despite efficient pull down of these recep-
tors by their respective antibodies (Figure 6E, lanes 3 and 5;nases. Receptor-specific immunoprecipitates from LN cells ex-
pressing FGFR-1 were compared to those expressing the respectively).
It remained important to examine whether the interaction ofPDGFR or VEGFR (Figure 6E). While N-cadherin is found at high
levels in FGFR-1 immunoprecipitates (Figure 6E, lane 2), it fails N-cadherin with FGFR-1 occurs in vivo in tumor cell lines which
endogenously express these molecules. FGFR-1 immunopre-to precipitate with either the PDGFR or VEGFR (Figure 6E, lanes
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Figure 6. The FGFR-1 and N-cadherin form a complex that is increased upon FGF-2 treatment
A: 293T cells were transfected with full length FGFR-1-Flag (lanes 1 and 3) or an empty vector (lane 2). Cells were lysed, N-cadherin was immunoprecipitated,
and the immunoprecipitates were electrophoresed and probed with an anti-Flag antibody (lanes 1–3). Control immunoprecipitates were carried out with
preimmune serum (lane 1).
B: N-cadherin-expressing L cells (LN) were transfected with FGFR-1-Flag, serum-starved for 4 hr, and then treated for 18 hr with 100 ng/ml FGF-2 and 5 g/
ml heparin (lane 2) or untreated (lane 1) and N-cadherin immunoprecipitates were probed with anti-Flag antibodies.
C: Immunoprecipitates were performed as in B and were probed with anti-FGF-2 antibodies.
D: Immunoprecipitates were performed using an anti-Flag antibody to pull down tagged FGFR-1 from LN cells and were probed with anti-phosphotyrosine
antibodies.
E: The FGFR-1-Flag, PDGFR, or VEGFR constructs were transfected into LN cells, immunoprecipitated with specific receptor antibodies, immunoblotted with
anti-N-cadherin antibodies (lanes 2, 4, and 6), stripped, and reprobed with anti-receptor antibodies (lanes 1, 3, and 5). Molecular weights are indicated.
cipitates from the tumor cells that express N-cadherin; MDA- 6). MMP-2 expression was unaffected by the same treatment
(Figure 7C, lanes 4–6). Thus, the results with the TSU.Pr-1 cellsMB-134, TSU.Pr-1, and MeWo exhibited strong reactivity with
N-cadherin (Figure 7A, top panel, lanes 2, 4, and 6). In contrast, are consistent with our findings with MCF-7 breast cancer cells.
A similar analysis of the N-cadherin-expressing MeWo cellsFGFR-1 immunoprecipitates from cells lacking N-cadherin,
such as ZR-75-1, DU145, or 888, did not show any background shows that they invade Matrigel at high rate in the absence of
FGF-2 and do not display enhanced invasion in response toreactivity with N-cadherin (see Supplemental Data at http://
www.cancercell.org/cgi/content/full/2/4/301/DC1). FGFR-1 FGF-2 (Figure 7B, right panel). Accordingly, these cells secrete
high amounts of MMP-2 in the absence or presence of FGF-2was efficiently precipitated in all cell lines (Figure 7A, bottom
panel, lanes 2, 4, and 6). Control IgGs did not immunoprecipitate (Figure 7C, lanes 7–8). PD98059 did not reduce the invasion
of MeWo cells (Figure 7B), although it weakened the MMP2the FGFR-1 or N-cadherin in any of the cell lines tested (Figure
7A, lanes 1, 3, and 5). production of these cells (Figure 7C, lane 9). These results are
in agreement with published data, showing that MeWo cell inva-We tested whether endogenous complex formation be-
tween N-cadherin and the FGFR-1 is associated with invasive sion depends on the p38-MAPK pathway (Denkert et al., 2002).
We speculate that the N-cadherin/FGFR-1/ERK pathway is notcapacity and MMP-9 production. The N-cadherin-expressing
cell line, TSU.Pr-1, exhibited an increase in Matrigel invasion the predominant pathway for the invasion of these cells.
We found that the MDA-MB-134 breast carcinoma cell lineafter FGF-2 stimulation, which was reduced by treatment with
the MEK1 inhibitor PD98059 (Figure 7B, left panel). Accordingly, did not exhibit any quantifiable invasiveness in Matrigel before
or after FGF-2 treatment (not shown). This is consistent withFGF-2 also caused an increase in MMP-9 expression (Figure
7C, lanes 4–5), which was reversed by PD98059 (Figure 7C, lane the lack of MMP-9 induction by FGF-2 (Figure 7C, lanes 1–2).
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Figure 7. Endogenous complex formation between N-cadherin and FGFR-1 can be associated with increased invasion of tumor cell lines
A: 3 mg lysate from N-cadherin expressing breast (MDA-MB-134), bladder (Tsu.Pr-1), or melanoma (MeWo) cell lines were immunoprecipitated with anti-
FGFR-1 rabbit antibodies (lanes 2, 4, and 6) or with normal rabbit IgG (lanes 1, 3, and 5). Immunoprecipitates were electrophoresed and probed with anti-
N-cadherin (top panel) or stripped and probed with anti-FGFR-1 (bottom panel).
B: Matrigel invasion of TSU.Pr-1 and MeWo cells in response to FGF-2 with or without PD98059.
C: Zymmogenic activity of MDA-MB-134 (lanes 1–3), TSU.Pr-1 (lanes 4–6), or MeWo cells (lanes 7–9) in response to 18 hr treatment with 100 ng/ml FGF-2 in
the absence or presence of 40 M PD98059.
This suggests that although MDA-MB-134 cells express FGFR-1 in a similar fashion. We cotransfected Flag-tagged ex-
tracellular or intracellular N-cadherin domains with untaggedN-cadherin and FGFR-1 and exhibit persistent MAPK-ERK acti-
vation by FGF-2, they may be deficient in signaling pathways FGFR-1 in 293T cells and isolated the resulting complexes by
immunoprecipitation with anti-Flag antibodies. FGFR-1 copre-that converge with MAPK-ERK, or in downstream effectors of
ERK, to produce the invasive response. cipitated only with N-cad-ECD (Figure 8B, top panel, lane 1)
but not with N-cad-ICD (Figure 8B, top panel, lane 2). -catenin,
which binds to the intracellular domain of N-cadherin, was foundAn extracellular complex between N-cadherin and the
complexed to N-cad-ICD as expected (Figure 8B, bottom panel,FGF receptor
lane 2). N-cad-ECD did not coprecipitate with -catenin (FigureWe examined whether N-cadherin and the FGFR-1 interact via
8B, bottom panel, lane 1).their extracellular or intracellular moieties. Flag-tagged FGFR-1
To determine which sites on the extracellular domain ofextracellular or intracellular domains were transfected into 293T
FGFR-1 interact with N-cadherin, we constructed deletions ofcells and analyzed for their ability to coprecipitate with endoge-
each of the three extracellular Ig-like domains of FGFR-1 (Figurenous N-cadherin. The extracellular FGFR-1-Flag (FGFR-ECD)
8C). Since the HAV motif within the second Ig-like domain (D2)coprecipitated with N-cadherin with high efficacy (Figure 8A,
of FGFR-1 has been postulated to be required for the interactionlane 1). In contrast, the FGFR-1-Flag intracellular domain (FGFR-
of FGFR-1 with N-cadherin (Doherty and Walsh, 1996; WilliamsICD) was not found in N-cadherin immunoprecipitates (Figure
et al., 1994), we tested the effect of HAV mutagenesis, replacing8A, lane 2). All cells expressed the transfected FGFR-1 con-
Ala 146 with Glu, on the interaction of FGFR-1 with N-cadherin.structs at similar levels and all reactions contained similar
Mutating HAV to HEV did not prevent the coprecipitation of theamounts of immunoprecipitated N-cadherin (not shown).
We mapped the region of N-cadherin that interacts with FGFR-ECD with N-cadherin in 293T cells (Figure 8D, lane 3
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Figure 8. FGFR-1 interacts with N-cadherin extracellularly, through the Ig domains 1 and 2 of the FGFR-1 extracellular domain
A: An FGFR-1-Flag extracellular domain construct (FGFR-ECD; lane 1) or an FGFR-1-Flag intracellular domain construct (FGFR-ICD; lane 2) was transfected
into 293T cells and analyzed for its ability to coprecipitate with endogenous N-cadherin.
B: 293T cells were cotransfected with N-cad-ECD-Flag (lane 1) or N-cad-ICD-Flag (lane 2) and an untagged FGFR-1 construct. Flag immunoprecipitates
were electrophoresed and probed with anti-FGFR-1 antibodies (top) or -catenin (bottom) antibodies.
C: Schematic diagram of the FGFR-ECD Flag deletion constructs. Residues are numbered beginning with the first residue of the mature protein minus the
signal sequence.
D: Each FGFR-ECD Flag deletion construct was transfected into 293T cells and analyzed for its ability to coprecipitate with the endogenous N-cadherin in
these cells. N-cadherin immunoprecipitates were probed with anti-Flag (top panel) or with anti-N-cadherin (middle panel). Starting lysates were probed
with anti-Flag to verify expression levels.
E: FGFR-ECD Flag deletion constructs were analyzed for their ability to bind FGF-2 after transfection into 293T cells. Detergent extracts from cells treated or
not treated with 100 ng/ml FGF-2 in the absence of heparin for 18 hr were immunoprecipitated with anti-Flag antibodies and probed with an anti-FGF-2
antibody.
compared to lane 2). As expected, the HAV-mutated FGFR-1 FGFR-1 Ig-like domain (D1) abolished the coprecipitation of
FGFR-ECD-Flag with N-cadherin (Figure 8D, lane 4). Deletiondid not bind FGF-2 (Plotnikov et al., 2000) (Figure 8E, lane 3).
Thus, the HAV motif in FGFR-1 is not critical for the interaction of domain 2 (D2) also inhibited the coprecipitation of FGFR-
ECD with N-cadherin (Figure 8D, lane 5), but deletion of domainof FGFR-1 with N-cadherin. In contrast, deletion of the first
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3 (D3) did not prevent FGFR-ECD from associating with shall, 1995). The mechanism whereby N-cadherin inhibits
FGFR-1 internalization remains to be determined. One possibil-N-cadherin (Figure 8D, lane 6), suggesting that D3 is not involved
in the recognition of N-cadherin by FGFR-1. Thus, the interac- ity is that N-cadherin perturbs the assembly of clathrin-adaptor
complexes with FGFR-1, thus preventing the endocytosis oftion of FGFR-1 with N-cadherin requires both the D1 and D2
domains. ligand-occupied FGFR into the clathrin-coated vesicles.
We found that the FGF receptor interacts extracellularly withTo control for the correct folding of the various FGFR-ECD
deletion constructs, we tested their ability to bind ligand after N-cadherin via its first two Ig-like domains, D1 and D2. In con-
trast, D3 does not appear to be involved in the association oftransfection into 293T cells (Figure 8E). D1, as expected,
bound FGF-2 (Figure 8E, lane 4) with even greater efficacy than N-cadherin with FGFR-1. It is thought that D1 of FGFR-1 inter-
acts intramolecularly with the ligand binding sites in D2 and D3the FGFR-ECD (Figure 8E, lane 2), while D2 or D3 were
incapable of ligand binding (Figure 8E, lanes 5 and 6), consistent and interferes with FGF binding (Plotnikov et al., 1999). Thus,
binding of N-cadherin to D1 and D2 may prevent intramolecularwith the requirement of both of these domains for ligand interac-
tion (Plotnikov et al., 2000). All of these constructs were effi- association of these domains, relieving FGFR-1 autoinhibition,
and resulting in enhanced sensitivity to ligand. In support ofciently transported to the cell surface after transfection, as deter-
mined by anti-Flag immunofluorescence (not shown). this model, MAPK-ERK activation occurred at substantially
lower levels of FGF-2 in cells expressing N-cadherin than in
control cells. The importance of D1 in modulating FGFR-1 func-Discussion
tion is underscored by the fact that D1 deletions have been
observed in pancreatic and squamous tumors as a result ofWe have shown that N-cadherin can promote invasiveness of
tumor cells by a mechanism involving more than a change in alternative FGFR-1 mRNA splicing, giving a possible selective
advantage to tumors (Kobrin et al., 1993; Yamaguchi et al.,cellular adhesion. A cascade of signaling events activated by
FGF-2 and dependent on N-cadherin results in expression of 1994). We thus hypothesize that tumor cells may acquire
N-cadherin as an alternative or additional mechanism to reverseextracellular proteases as well as cellular invasion. N-cadherin
associates with the FGFR-1 at the cell surface and attenuates the negative effect of D1 on FGFR-1 and enhance receptor
outputs.ligand-induced receptor downregulation, leading to increased
FGFR-1 stability, persistent expression of FGFR-1 at the cell The interaction between N-cadherin and FGFR-1 has been
suggested to be mediated by the HAV motif within D2 of FGFR-1surface, sustained MAPK-ERK activation, MMP-9 gene expres-
sion, and tumor cell invasion. and the extracellular domain 4 (EC4) of N-cadherin (Kim et al.,
2000; Williams et al., 2001). We found that mutagenesis of HAVThe difference between FGF-2 and other growth factors in
inducing MMP-9 expression lies in the ability of FGF-2 to acti- to HEV did not disrupt the physical association of FGFR-1 with
N-cadherin, suggesting that the HAV in FGFR-1 may not bevate sustained MAPK in the presence of N-cadherin. These
results are consistent with evidence suggesting that the time required for the functional cooperation of these molecules. In
support of our finding, the crystal structure of FGFR-1 indicatescourse of signaling by ligand-activated receptors determines
both amplitude and specificity of the output (Marshall, 1995; that the HAV tri-peptide may not engage in protein interaction,
since it is buried in a hydrophobic pocket (Plotnikov et al.,Simon, 2000). For instance, PC12 cells proliferate when treated
with EGF and differentiate in response to NGF. Both events 1999). Since neither D1 or D2 alone were capable of recognizing
N-cadherin, we propose that a larger site on the FGFR-1, con-require MAPK phosphorylation, but with differential kinetics.
Namely, while EGF causes a transient activation of ERK2, NGF tributed by D1 and D2, interacts with the EC4 domain of
N-cadherin.stimulates sustained ERK2 phosphorylation (Marshall, 1995).
Similarly, differential activation of MAPK by pheromones in yeast While we emphasize the critical role played by the MAPK-
ERK pathway in breast cancer invasion in response todiscriminates between mating and invasive growth as a result of
transient versus persistent activation of the ERK kinase homolog N-cadherin and FGF-2, we do not rule out other signaling path-
ways that may contribute to or prevent metastasis. Blockade(Sabbagh et al., 2001). Thus, while different stimuli may lead to
MAPK phosphorylation, differences in the duration of the signal of MAPK-ERK signaling in N-cadherin expressing cells resulted
in suppressing the FGF-2-induced invasion and MMP-9 expres-can result in diversity of cellular programs (Marshall, 1995;
Schaeffer and Weber, 1999). Others have also shown that sion, but not migration, suggesting that a pathway other than
ERK might be transducing the motility of cells in response togrowth factor stimulation of invasive growth was promoted by
increased and sustained MAPK in breast tumor cells (Krueger FGF-2. Consistent with this hypothesis, the FGFR has been
shown to stimulate the PI3-kinase pathway, known to play aet al., 2001). While we have focused on the MAPK-ERK pathway,
we do not exclude the involvement of other MAP kinases such role in cell motility (Sotsios and Ward, 2000; Wu et al., 2000).
Another potential candidate could be PLC, which is alsoas the p38 and JNK stress-induced cascades in cancer invasion,
of which the latter was shown to influence cell motility in re- thought to regulate cancer cell motility and invasion (Kassis et
al., 1999; Wu et al., 2000) as well as neurite outgrowth depen-sponse to cytokines (Xia et al., 2000).
Exposure of cells or tissues to growth factors leads to the dent on N-cadherin and the FGFR (Doherty and Walsh, 1996).
We hence speculate that combined signaling by FGFR-1 andinternalization of receptors by a clathrin-dependent mechanism
and to receptor degradation by the endocytic pathway (Ceresa N-cadherin may involve mobilization of several downstream
molecules, including MAPK-ERK, PI3-kinase, and PLC, to pro-and Schmid, 2000). Our study suggests that N-cadherin en-
hances FGFR-1 signaling by attenuating ligand-induced inter- duce an invasive outcome. On the other hand, the fact that no
correlation between sustained ERK activation and invasion wasnalization. In support of our findings, others have suggested
that MAPK activity could be sustained as a result of reduced found in the MDA-MB-134 cancer cells suggests perhaps that
some tumor cells are deficient in downstream targets of ERKinternalization or overexpression of cell surface receptors (Mar-
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Immunoblotting and immunopreciptationthat transactivate MMP-9 gene transcription or have developed
Cells were serum starved for 18 hr before adding growth factors. Cells wereadditional pathways that counteract metastasis.
extracted in solubilization buffer (50 mM Tris-HCL [pH 7.5], 150 mM NaCl,
Finally, we postulate that the FGFR may either suppress or 0.5 mM MgCl2, 0.2 mM EGTA, 1% Triton X-100) including protease inhibitors.
activate invasive growth depending on the adhesion molecule Twenty g of protein was loaded on 7.5% SDS-polyacrylamide gels and
that it binds to. Namely, while N-CAM was shown to restrict transferred to nylon membranes. Blots were probed with indicated antibodies
and developed with chemiluminescence. Immunoprecipitations were donetumor invasion by inducing FGFR-4 signaling (Cavallaro et al.,
by incubation of 1–2 mg lysate from each indicated cell line, with primary2001), N-cadherin is shown to promote invasion by enhancing
antibody overnight at 4C and addition of 5 mg Protein-A-sepharose beads
FGFR-1 signaling. The opposite effects of N-CAM and for 1 hr at 4C, followed by three washes in solublization buffer and extraction
N-cadherin on tumor metastasis may be due to differential mobi- of beads in 30 l sample buffer at 100C for 5 min.
lization of downstream signaling events (Cavallaro et al., 2001).
Invasion and migrationAltogether, our findings provide valuable insights into the
The ability of cells to migrate through Matrigel-coated filters (invasion) ormolecular aspects of tumor metastasis. It appears that the asso-
through uncoated fiters (migration) was determined as described (Hazan etciation of adhesion molecules with growth factor receptors pro-
al., 2000).
vides tumor cells with an important platform to create diversity
in signaling events that differentially lead to adhesion, migration, Substrate gel electrophoresis
Secreted metalloproteinases were detected by zymmography (Nakajima etinvasion, and metastasis.
al., 1995) as described (Hazan et al., 2000).
Experimental procedures
Receptor internalization
L and LN cells were transiently transfected with FGFR-1 and seeded in 24Cell lines
well plates at 5  104 per well until confluence and were then serum-starvedCell lines were obtained from the American Type Culture Collection (ATCC)
and incubated with 0.5 ml DMEM/1% BSA including 100 ng/ml FGF-2 andexcept as noted. The TSU.Pr-1 bladder carcinoma cell line (van Bokhoven
5 g/ml heparin for 2 hr on ice. Cells were then washed with cold PBS toet al., 2001) was from Dr. John Isaacs at Johns Hopkins University. The
remove unbound FGF-2 and placed at 37C for various time points. At eachmelanoma cell line 888 was from Dr. Paul Robins at the National Institutes
time point, the remaining surface-bound FGF-2 was stripped from the cellof Health. The melanoma cell line MeWo was from Dr. Soldano Ferrone from
surface using ice cold 20 mM acetic acid/2 M NaCl for 2 min (Wong etthe Roswell Park Cancer Institute. L cell lines were from Dr. David Colman
al., 2002), TCA-precipitated, electrophoresed, and immunoblotted with anat Mount Sinai School of Medicine.
antibody to FGF-2. To confirm that all samples contained the same number
of cells, the levels of -tubulin were determined in each monolayer after
Reagents stripping of FGF-2. Blots were scanned and FGF-2 levels were quantified
Growth factors were from Pepro Tech. Biocoat inserts were from Becton- by densitometry. Data were expressed as the percent of the levels of FGF-2
Dickinson. PD 98059 was from NEB. GM 6001 was from Calbiochem. Mono- before transfer of cells to 37C.
clonal anti-N-cadherin antibodies were from Zymed laboratories. Polyclonal
anti-N-cadherin antibodies were from Dr. David Colman. Anti-phospho- Receptor degradation
MAPK (ERK-1/2) was from NEB and anti-total-MAPK from Santa-Cruz. L and LN cells were transfected as above and incubated with DMEM with
Monoclonal anti-Flag-tag antibody and anti--tubulin were from Sigma. 20 g/ml cycloheximide and 100 ng/ml FGF-2 for 1 to 9 hr. At each indicated
Polyclonal anti-FGFR-1 and 2 and EGFR and VEGFR antibodies were ob- time, cell lysates harvested, the protein was determined, and 30 g was
tained from Santa Cruz. Polyclonal antibodies to the FGFR-1 extracellular electrophoresed and immunoblotted with anti-FGFR-1 antibodies. Immu-
domain, monoclonal anti-FGF-2, anti-phosphotyrosine, and anti-PDGFR an- noblots were scanned and the intensity of the protein bands was determined
tibodies were from Upstate Biotechnology. by densitometry. Data were normalized to the values of endogenous
-tubulin and expressed as the percent of the levels of FGFR-1 before
addition of FGF-2.Constructs
Expression plasmids for the human EGFR or PDGFR  or  and a retroviral
FACS analysisconstruct expressing constitutively active MEK1 (MEKEL) were from Dr.
Adherent monolayers of each indicated cell line that were incubated inStuart Aaronson (Mount Sinai School of Medicine). A dominant negative
serum-free media for 18 hr with or without 100 ng/ml FGF-2 and 5 g/mlMEK1 was from Dr. Silvio Gutkind (National Institutes of Health). The human
heparin were made into single cell suspensions using 5 mM EDTA/PBS.VEGFR construct was from Dr. Bruce Terman (Albert Einstein College of
Cells were washed in PBS and 1  106 cells incubated for 30 min at 4CMedicine). The full-length human FGFR-1 cDNA was from Dr. Joseph Schles-
in 0.5 ml PBS/0.5% BSA containing either a 1:100 dilution of an anti-FGFR-singer (NYU).
1 extracellular peptide antibody (UBI), or of a preimmune anti-sera (UBI).The FGFR-1 full length and extracellular (FGFR-ECD) cDNA were sub-
Cells were washed in cold PBS and incubated with secondary anti-rabbit-cloned by PCR into Not 1/Bam H1 restriction sites downstream of the CMV
FITC antibodies at 1:100 in 0.5 ml PBS/0.5% BSA for 30 min on ice, washed
promoter and upstream of the c-terminal Flag-tag sequence in the expres-
in cold PBS, and analyzed by flow cytometry. The histogram plots for the
sion vector pFLAG-CMV-5a. The intracellular domain of FGFR-1 (FGFR-ICD)
FGF-2 treated and untreated samples labeled with the anti-FGFR-1 antibody
was subcloned by PCR into a pFLAG-CMV-1 vector (Sigma). This construct
were superimposed on to those from identical samples stained with the
included an N-terminal Flag-tag sequence fused to the signal sequence preimmune antibody using the Cell Quest software program. Experiments
of preprotrypsin. Expression plasmids of FGFR-1-ECD deletions of Ig-like were performed at least in triplicate. Increase or decrease in FGFR surface
domains 1–3 (D1, D2, and D3) and site-directed mutagenesis (HAV to expression was expressed as the ratio of the mean channel number of cells
HEV) were constructed using PCR and three-fragment ligation. Mutation of stained with anti-FGFR-1 after culture in the presence or absence of FGF-2.
HAV to HEV in FGFR-1-ECD was performed by PCR site-directed mutagene-
sis with single nucleotide mutation and ligated to a Hind III/BamH1 cleaved Luciferase assay
pFLAG-CMV-5a vector. Full-length Flag-tagged human N-cadherin (hN-cad) The MMP-9 promoter plasmid was obtained from Dr. Boyd at MD Anderson
was produced by PCR of the human N-cadherin cDNA (Dr. John Hemperly, Cancer Center. Vector- and N-cadherin-expressing MCF-7 cells were tran-
Becton-Dickinson). Flag-tagged human N-cadherin extracellular domain siently cotransfected with 0.5 g of the MMP-9 reporter plasmid and 0.5
(N-cad-ECD) was created by a similar strategy. N-cadherin intracellular do- g of MFG--galactosidase gene plasmid (Dr. Toru Ouchi, Mount Sinai
main (N-cad-ICD) was ligated in pFLAG-CMV-1, which contains an N-ter- School of Medicine) using Lipofectamine-plus (Gibco). Cells were serum-
starved 24 hr posttransfection for 4 hr and treated with or without FGF-2minal Flag-tag sequence fused with the signal sequence of preprotrypsin.
312 CANCER CELL : OCTOBER 2002
A R T I C L E
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